Author:
Guclu Ertugrul,Tuna Nazan,Karabay Oguz,Akhan Sıla,Bodur Hurrem,Ceylan Bahadır,Demirdal Tuna,Demirdag Kutbettin,Demirturk Nese,Ekerbicer Hasan,Erol Serpil,Esen Saban,Evirgen Omer,Geyik Mehmet Faruk,Gunduz Alper,Karahocagil Mustafa Kasım,Kokoglu Omer Faruk,Ozdemir Davut,Ozgunes Nail,Sargın Fatma,Tosun Selma,Tutuncu Ediz
Abstract
Introduction: Although pegylated interferons (pegIFNs) alpha-2a and alpha-2b have been used in chronic hepatitis B (CHB) treatment for many years, there are few studies concerning predictors of sustained virologic response (SVR) to pegIFN therapy. In this study, we aimed to investigate the predictors of response to pegIFN treatment in cases with HBeAg-negative CHB infection. Methodology: Seventeen tertiary care hospitals in Turkey were included in this study. Data from consecutively treated HBeAg-negative CHB patients, who received either pegIFN alpha-2a or alpha-2b, were collected retrospectively. SVR is defined as an HBV DNA concentration of less than 2,000 IU/mL six months after the completion of therapy Results: SVR was achieved in 40 (25%) of the 160 HBeAg-negative CHB patients. Viral loads in patients with SVR were lower compared to those with no SVR, beginning in the third month of treatment (p < 0.05). The number of cases with a decline of 1 log10 IU/mL in viral load after the first month of treatment and with a serum HBV DNA level under 2,000 IU/mL after the third month of treatment was higher in cases with SVR (p < 0.05). The number of patients who had undetectable HBV DNA levels at week 48 among responders was significantly greater than among post-treatment virological relapsers (p < 0.05). Conclusions: Detection of a 1 log10 decline in serum HBV DNA level at the first month of treatment and a serum HBV DNA level < 2000 IU/mL at the third month of therapy may be predictors of SVR.
Publisher
Journal of Infection in Developing Countries
Subject
Virology,Infectious Diseases,General Medicine,Microbiology,Parasitology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献